Clinical trials: Cancers, Pain
Low Back Pain, Chronic Pain
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
The purpose of this 52-week open label study is to determine the long-term safety of a new opioid molecule, NKTR-181, in patients with moderate to severe chronic low back pain or chronic non-cancer pain.
- Trial name
- SUMMIT-LTS (NCT02367820)
- Testing
- NKTR-181 BID tablets
- Where
- 56 sites in United States
- Volunteers
- 638 people
- Sponsor
- Nektar Therapeutics
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-2 (NCT01522443)
- Testing
- cabozantinib, mitoxantrone, prednisone
- Where
- 82 sites in United States, Australia and 3 more
- Volunteers
- 119 people
- Sponsor
- Exelixis
Pain, Neoplasms
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release…
- Conditions
- Pain, Neoplasms, Chronic Pain
- Trial name
- CORAL (NCT01964378)
- Testing
- Cebranopadol, Morphine Prolonged Release
- Where
- 42 sites in Austria, Belgium and 12 more
- Volunteers
- 200 people
- Sponsor
- Tris Pharma, Inc.
Advanced Lung Cancer
A Clinical Study of Pain and Discomfort Associated With Advanced Lung Cancer
In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.
- Trial name
- NCT05852002
- Testing
- 35 kDa hyaluronan fragment
- Where
- Mongolia
- Volunteers
- 10 people
- Sponsor
- Nakhia Impex LLC
Pain
Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute
As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.
- Trial name
- NCT01982539
- Testing
- Zipsor®
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Breast Cancer, Arthralgia
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)
- Conditions
- Breast Cancer, Arthralgia, Osteoporosis
- Trial name
- ART2 (NCT00497458)
- Testing
- Testosterone
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Havah Therapeutics Pty Ltd
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections.
- Conditions
- Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
- Trial name
- NCT06848348
- Testing
- Halneuron, Halneuron (Open Label Extension)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dogwood Therapeutics Inc.
Cancer Pain
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorohone Hydrochloride (HCl) compared with morphine sustain release (SR) in participants with chronic (lasting a…
- Trial name
- NCT00803283
- Testing
- Hydromprphone Hydrochloride (HCl) OROS, Morphine Sustain Release (SR)
- Volunteers
- 2 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Cancer Pain
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
The purpose of this is study to evaluate improvement of sleep disorder caused by cancer pain after the administration of Hydromorphone Oral Osmotic System (OROS) in Korean participants with cancer.
- Trial name
- NCT00766831
- Testing
- Hydromorphone
- Volunteers
- 190 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pain, Analgesics, Opioid
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain…
- Trial name
- NCT00410878
- Testing
- OROS Hydromorphone HCI (slow release)
- Volunteers
- 22 people
- Sponsor
- Alza Corporation, DE, USA
Cancer, Pain
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00833040
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Talphera, Inc
Prostate Cancer
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone…
- Trial name
- NCT00133224
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 408 people
- Sponsor
- Cell Genesys
Pain, Cancer
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
The purpose of this study is to evaluate the safety and efficacy of fentanyl one-day transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) in participants switched…
- Trial name
- NCT00641667
- Testing
- Fentanyl
- Where
- Japan
- Volunteers
- 66 people
- Sponsor
- Janssen Pharmaceutical K.K.
Pain, Cancer
Clinical Study of KW-2246 in Patients With Cancer Pain
This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.
- Trial name
- NCT00355628
- Testing
- KW-2246 (fentanyl citrate)
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Pain, Chronic Pain
Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.
Chronic Pain, especially neuropathic pain, are adverse events after posterolateral thoracotomy for lung resection. The continuous application of ketamine may have a prophylactic effect and helps to prevent chronic pain.
- Conditions
- Acute Pain, Chronic Pain, Neuropathic Pain
- Trial name
- NCT03105765
- Testing
- Ketamine
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Dr. Horst Schmidt Klinik GmbH
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
Intractable Pain, Neoplasms
NP2 Enkephalin For Treatment of Intractable Cancer Pain
The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease.
- Trial name
- NCT01291901
- Testing
- NP2
- Where
- 18 sites in United States
- Volunteers
- 33 people
- Sponsor
- Diamyd Inc
Pain, Pediatric Cancer
An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients
In this SBIR, ALTality, Inc. ("SpellBound") will assess the feasibility of a dual English/Spanish language augmented reality(AR)-enabled tool for assessing inpatient postoperative pain/nausea/vomiting in Hispanic/Latino children…
- Trial name
- NCT06635434
- Testing
- AR Pain assessment
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ALTality, Inc.
Sciatica, Herniated Disc
Study of REN-1654 in Patients With Sciatica Pain
The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with pain that radiates down the leg(s), and is typical of sciatica (lumbosacral radiculopathy).
- Conditions
- Sciatica, Herniated Disc, Radiculopathy
- Trial name
- NCT00107055
- Testing
- REN-1654
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Renovis
Pain, Cancer
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy.
- Conditions
- Pain, Cancer, Colonic Diseases
- Trial name
- NCT01926444
- Testing
- GIC-1001
- Where
- 15 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- gicare Pharma Inc.